Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS3232836 A
Publication typeGrant
Publication date1 Feb 1966
Filing date24 Aug 1959
Priority date24 Aug 1959
Publication numberUS 3232836 A, US 3232836A, US-A-3232836, US3232836 A, US3232836A
InventorsIezzoni Domenic G, Michael Carlozzi
Original AssigneePfizer & Co C
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine
US 3232836 A
Abstract  available in
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent FACELiTATiNG HEALING 0F BODY SURFACE WOUNDS BY ENTRAVENOUS ADMENISTRATION OF N-ACETYL GLUCOSAMENE, GLUCOSAMINE, 0R PHARMAQEUTECALLY ACQEPTABLE AQEID SALTS OF GLUJOSAMINE Michael Carlozzi, (Irani'ord, NJ and Domenic G. lozzoni, Garden City, N.Y., assignors to Chas. Pfizer & Co., linc., New York, N.Y., a corporation of Delaware No Drawing. Filed Aug. 24, 1959, Ser. No. 835,451

2 Claims. (Cl. 167-65) This invention relates to a new and useful process of promoting healing in the human body. More particularly, it relates to a new process of promoting healing in the human which comprises administering glucosamine and/ or glucosamine derivatives to a person with a wound of the body surface. It also relates to compositions useful therefor. This application is a continuation-in-part of our copending application Serial No. 795,617, filed on February 26, 1959, now abandoned.

The healing of wounds of the body surface whether caused by trauma or surgery often times presents considerable dificulty, as described in numerous articles appearing in the medical literature. Many persons exhibit a slow rate of healing during which time considerable care must be taken to avoid the possibility of infection. Even with persons of normal healing rate, protection against infection must be provided, necessitating exacting care by medical personnel. The present invention provides a new and effective process of facilitating the healing of Wounds of the body surface which materially reduces the time during which the possibility of infection is greatest as well as the time periods of close medical care and supervision. Other beneficial results of the present process are obvious from the following dis closure.

As previously mentioned, the process of the present invention comprises administering an effective amount of glucosamine and/or glucosamine derivatives to a subject with a wound of the body surface. While beneficial results will be noted with even lesser amounts, it is usually desirable to administer the glucosamine compound at a dosage of at least from about to about 20 grams per day for best results. Often times it is found advantageous to administer the glucosamine compound at dosages as high as 200 grams per day and even higher.

The physician will indicate daily dosage of the instant therapeutic agents. The dosage and the route of administration will depend upon the extent of the wound and the healing rate of the individual patient. At times, the present therapeutic agents may be administered orally or locally, i.e. into the Wound, and, at other times, parenterally, that is intravenously. Of course, these routes of administration may be employed concurrently to maintain an effective level of glucosamine compound in the subject patient. For example, the glucosamine compound may be administered to a patient orally at a dosage of from 10 to 20 grams per day for a period of four to five days before surgery, followed by intravenous administration at a dosage of between 100 to 200 grams in parenteral fluids, usually isotonic slaine, for four to five days postoperatively and then oral administration, as needed, of from 10 to 20 grams per day, usually for an additional four to five days.

The present invention contemplates the use of glucosamine, and/or glucosamine derivatives, such as lower N-alkanoylglucosamine, e.g. N-acetylglucosamine, phosphorylatedglucosamines, such as N-acetylglucosamine-6- phosphate, and glucosamine-G-phosphate, salt of glucosamine with pharmaceutically-acceptable acids, such as hydrochloric, phosphoric, citric, gluconic, acetic, malic and the like. A particularly effective, and, for this reason, preferred glucosamine derivative is N-acetylglucosamine. The therapeutic agent is conveniently administered in the form of a suspension or solution, although it may also be administered as tablets or capsules. For oral use, suspensions or solutions of the therapeutic agent in pharmaceuticaly acceptable liquid media are particularly effective. Such liquid media are well known in the art, for example, water, aqueous glycols, sugar solutions and the like which may contain conventional flavoring and coloring agents. Tablets and capsules may be prepared from mixtures of the present compounds with well known pharmaceutical excipients such as starch, sugar, tapioca, certain forms of clay, and the like. For intravenous use, the present compounds are administered in isotonic solutions, such as isotonic saline.

For intravenous use, the present invention provides sterile aqueous compositions for intravenous administration which are prepared by dissolving the selected agent in an isotonic (about 0.1%) saline solution. It is preferred to employ the glucosamine compound at a concentration ranging from about 2% to about 20%, and preferably from about 3% to about 10%. Of course, lower concentrations provide some beneficial results but necessitate the use of extremely large volumes of intravenous solution which is usually not desirable. Higher concentrations, although operable, provide no appreciable advantage and thus are not recommended. The present invention also provides sterile solid compositions of glucosamine and/ or glucosarnine derivative together with salt for reconstitution with water to provide the abovedescribed intravenous compositions. Of course, such solid compositions should contain a sufficient amount of salt to provide an isotonic saline solution when dissolved in Water, that is, an isotonic amount of salt. The solid compositions preferably contain salt and glucosarnine compound in a weight ratio ranging from about 1:20 to about 1:200. For example, when one gram of sodium chloride and 50 grams of N-acetylglucosamine aredissolved in one liter of Water, a 5% glucosamine isotonic saline solution is obtained. Other such isotonic solutions of the glucosamine compound are prepared by reconstitution of the present solid compositions.

As a result of the administration of a glucosamine compound as herein described, in addition to a remarkable improvement in healing time, patients generally show a sense of well being, maintain body weight and, in some instances, unexpected weight gains are obtained. Further, such patients exhibit positive nitrogen balance in place of the usually expected negative balance during immediate postoperative period. Additionally, there is noted a lowering of blood cholesterol.

The following exemplifies the eflicacy of the present new invention in promoting wound-healing. A female patient of 19 years of age and average weight with a mid-thigh amputation of a lower extremity suffered serious postoperative complications and poor wound healing. Daily intravenous administration of N-acetylglucosamine in isotonic saline g. dissolved in 3 liters per day) to this patient for 4 days followed by daily oral administration of 20 grams of N-acetylglucosamine for 5 days resulted in a marked improvement in general condition with rapid healing of the wound.

A male patient of 28 years of age and. average weight with postoperative septicemia and shock due to E. coli was being treated by hypothermia and with an artificial kidney for about three weeks. During this time his abdominal Wound, i.e. the original operative incision, remained opened and gaping. At this time, the patient was treated with N'acetylglucosamine intravenously for 4 days, daily dosage being 100 grams in 3 liters of isotonic saline, followed by oral administration of 20 grams of N-acetylglucosamine daily for 5 days, which resulted in excellent, rapid healing of the wound. Similar results are obtained with glucosamine and other glucos-a- 5 mine derivatives as hereinbefore described with human as well as animal subjects.

Similar results were obtained when the present process was used in the treatment of other surgical patients. A Process for facilitating healing of a Wound Of The results are summarized in the following table: m the body surface which comprises administering intra- [NA G N-acetylglucosamine] 2% glucosamine hydrochloride in 0.1% saline. 20% N-acetylglucosamine in 0.1% saline.

5% glucosamine phosphate in 0.1% saline. 5% glucosamine citrate in 0.1% saline.

10% glucosamine gluconate in 0.1% saline. 3% glucosamine acetate in 0.1% saline.

What is claimed is:

Premperative Serum trans- Blood Urine N Patient Diagnosis and operation treatment Post-operative treatment aminase units cholesterol, gm.

nigrn./l cc.

I. 49 WF Ulccrative colitis, Rx for NAG, 10 gm. daily 1st P.O. day, NAG, 100 Irc-cp. 21 2.4

several weeks with 300 for 4 days. gins. I.V.; 2d R0. day, 1st 19.0. 40 ion mgm. cortisone daily. WAG, 200 8. 3d 4th P.O. 23.. 4 500 No complications. Dis- 1&0. day, NAG, 250 gms. 10th R0. 11 145 .145 charged 11th l.0. day. I.V.; 4th P.O. day, NAG,

200 gms. I.V.

II. 63 CF Perforated peptic ulcer, 3 None NAG, 200 gm. I.V. daily Ire-op. 28 Hi 500 days duration. No comfor 5 days. 1st R0. 47 190 .720 plications. Discharged 4th R0. 26.. 1:3 .300 12th P.O. day. th P.O. l2. 110 100 III. 63 CM Subtotal gastrectomy NAG, 10 gm. daily NAG, 200 gin. I.V. daily Pre-op. 19... 204 .100 chronic duodenal ulcer. for 4 days. for 3 days. 1st PD. 41 210 100 Discharged 8th P.O. day. t P.O. 10 180 Balance No complications. 8th P.O. 4 a. 170 Balance IV. 39 C11... Acute+ohronic cholecystitis None NAG, 200 gm. I.V. daily Pre-op. 24 142 .400 cholecystectomy. No for 3 days. 1st 1.O. 31 100 .400 complications. Discharg- 4th P.O. 20.. 160 100 ed 10th I.O. day. 10th P.O. 8 130 Balance venously from about 100 to about 200 grams of a compound selected from the group consisting of N-acetyl glucosamine, glucosamine and pharmaceutically acceptable acid salts of glucosamine.

2. A process for facilitating healing of a body wound of the body surface which comprises administering intravenously an effective amount of N-acetyl glucosaniine.

As it is obvious to those skilled in the art other therapeutically effective agents may be co-administered with the present agents, for example, compounds which serve as a source of high-energy phosphorus. Exemplary of this type of compound are phosphoenolpruvic acid and adenosine phosphates, e.g. mono and di-phosphates, which aid in the phosphorylation of intermediates in the metabolism of carbohydrate. Other such therapeutic agents may similarly be employed, e.g. broad spectrum Referemes Cited y the Examine! antibioticssuch as tetracycline, oxytetracycline ascorbic UNITED STATES PATENTS 3 tyrosmei 2,710,806 6/1955 Gyorgy 99 54 rhe following examples are given by way of illustra- 2 786 051 3/1957 Gyorgy 260 2115 tion and are not to be construed as limitations of the 28O2819 8/1057 Ledemr g 3 I present invention, many variations of which are possible 2832766 4/1558 wolfrom without departing from the spirit or scope thereof. 411 4/1959 HeynS 260 211 Example 1 2,910,408 10/1959 Pope et al. 26021l 2 980 584 4/1961 Hammer 16765 A mixture of 100 g. of N-acetylglucosamine and 1 g. of 7 sodium chloride is thoroughly blended in a twin shell 299747l 8/1961 Cheney et a1 260' 2472 blender in an ethylene oxide-carbon dioxide atmosphere. The mixture is stored in an infusion bottle for reconstitution with one liter of sterile water for intravenous administration.

Other such mixtures are prepared in the same manner to provide solid compositions containing the following weight proportions of salt to glucose compound:

OTHER REFERENCES Anglesio, E., et al., Effects of Carcinostatic and Other Biologically Active Compounds in the Normal Rat, Cancer Research, vol. 18, No. 1, pp. 113l16 (1959).

Baratella, Sullmpiego di Un Nuovo tipo di Latte in Polvere Integrato Con Fattore Bifidus e Vit. B12 Clinica Pediatrica (Bologna), vol. 40, No. 1, pp. 39-40,

1 part salt to 50 parts glucosamine. 1 part salt to 100 parts glucosamine hydrochloride. 1 part salt to 200 parts glucosamine phosphate.

1 part salt to 20 parts N-acetylglucosamine.

Example II January 1958.

Boas, N., et al.,

vol. 88, No. 3, pp. 454457, March 1955.

Boyer et al., The Enzymes vol. 1, 2nd edition Academrate of intravenously Administered Glucosamine in the Rat, Proc. Soc. Exp. Biol. and Med,

(Other references on following page) Two thousand grams of N-acetylglucosamine is added to 20 liters of 0.1% aqueous saline solution. The resulting solution is filtered through a Seitz filter and stored in infusion bottles each containing one liter of 10% solution. The solution is useful for intravenous administration to human hosts with a wound of the body surface.

Example 111 The procedure of Example 11 is repeated to prepare the following solutions:

20% glucosamine in 0.1% saline. 3% N-acetylglucosainine in 0.1% saline.

5 OTHER REFERENCES 249-265, pages 4, 7-8, 29-34, 257-260 are especially pertinent.

Paschoud, Experimentelle Untersuchungen Zur Heparin-Genese Der Urticaria Pigmentosa, Dermatologica (Basel), vol. 108, No. 46, pp. 361-365 (1954).

Reed, Efiect of Cortisone on the Postive Potentiais Induced by Glucosamine and Amino Purines in the 6 Synovial Cavities of Dogs, Am. J. PhysioL, vol. 168, pp. 820-824 (1952).

Thian et a1., Prophylactic Use of G1ucosamine-Potentiated Antibiotics in Emergency Abdominal and Gas trointestinal Surgery, 1. Louisiana Med. Soc., vol. III, No. 2, pp. 49-50 (February 1959).

LEWIS GOTTS, Primary Examiner.


Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2710806 *22 Apr 195214 Jun 1955American Home ProdFood compositions
US2786051 *18 Apr 195219 Mar 1957American Home ProdGrowth-promoting substances and their recovery
US2802819 *13 Jul 195413 Aug 1957Ciba Pharm Prod IncAcylated products
US2832766 *17 Apr 195229 Apr 1958Univ Ohio State Res FoundSulfated aminopolysaccharides
US2884411 *29 Jul 195428 Apr 1959Corn Products CoPreparation of a glucosamine
US2910408 *28 Dec 195627 Oct 1959American Home ProdProduction of n-acetylglucosamine
US2980584 *29 Oct 195718 Apr 1961Pfizer & Co CParenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US2997471 *18 Aug 195822 Aug 1961Bristol Myers CoTetracycline derivatives
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3328258 *9 Sep 196327 Jun 1967LiphaAnti-microbial therapeutics consisting of nitrofurantoin, tetracycline, and d-glucosamine
US3903268 *19 Feb 19712 Sep 1975Lescarden LtdChitin and chitin derivatives for promoting wound healing
US3911116 *19 Jul 19737 Oct 1975Balassa Leslie LProcess for promoting wound healing with chitin derivatives
US3914413 *9 Jul 197321 Oct 1975Leslie L BalassaProcess for facilitating wound healing with N-acetylated partially depolymerized chitin materials
US4006224 *29 Sep 19751 Feb 1977Lescarden Ltd.Method and agent for treating inflammatory disorders of the gastrointestinal tract
US4642340 *30 Apr 198210 Feb 1987Rotta Research Laboratorium S.P.A.Stable compounds of glucosamine sulphate
US4647453 *25 Sep 19853 Mar 1987Peritain, Ltd.Treatment for tissue degenerative inflammatory disease
US4772591 *16 Apr 198620 Sep 1988Peritain, Ltd.Method for accelerated wound healing
US5364845 *31 Mar 199315 Nov 1994Nutramax Laboratories, Inc.Glucosamine, chondroitin and manganese composition for the protection and repair of connective tissue
US5587363 *14 Mar 199424 Dec 1996Nutramax Laboratories, Inc.Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
US5804594 *22 Jan 19978 Sep 1998Murad; HowardPharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5972999 *3 Sep 199826 Oct 1999Murad; HowardPharmaceutical compositions and methods for improving wrinkles and other skin conditions
US625529528 Apr 19973 Jul 2001Nutramax Laboratories, Inc.Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
US62712137 Feb 19977 Aug 2001Nutramax Laboratories, Inc.Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue
US635853918 Aug 200019 Mar 2002Howard MuradPharmaceutical compositions for reducing the appearance of cellulite
US6440465 *1 May 200027 Aug 2002Bioderm, Inc.Topical composition for the treatment of psoriasis and related skin disorders
US649234923 Dec 199610 Dec 2002Nutramax Laboratories, Inc.Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
US658312316 Apr 200124 Jun 2003Nutramax Laboratories, Inc.Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue
US667697722 Jan 200213 Jan 2004Howard MuradPharmaceutical compositions and methods for reducing the appearance of cellulite
US66931888 Aug 200117 Feb 2004Cargill IncorporatedN-acetyl-D-glucosamine and process for producing N-acetyl-D-glucosamine
US741388115 Jun 200519 Aug 2008Cargill, IncorporatedChitosan and method of preparing chitosan
US74888122 Apr 200310 Feb 2009Cargill, IncorporatedChitosan production
US767062028 Jun 20022 Mar 2010Bioderm, Inc.Topical composition for the treatment of psoriasis and related skin disorders
US781651413 Oct 200319 Oct 2010Cargill, IncorporatedGlucosamine and method of making glucosamine from microbial biomass
US792343731 Mar 200612 Apr 2011Cargill, IncorporatedWater soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
US803492518 Mar 201011 Oct 2011Cargill, IncorporatedGlucosamine and method of making glucosamine from microbial biomass
US8152750 *13 Sep 200410 Apr 2012Marine Polymer Technologies, Inc.Vascular access preservation in hemodialysis patients
US822223231 Mar 200617 Jul 2012Cargill, IncorporatedGlucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass
US848151216 Jun 20109 Jul 2013Marine Polymer Technologies, Inc.Compositions and methods for modulation of vascular structure and/or function
US88595281 Jul 201314 Oct 2014Marine Polymer Technologies, Inc.Compositions and methods for modulation of vascular structure and/or function
US89924538 Mar 201231 Mar 2015Marine Polymer Technologies, Inc.Vascular access preservation in hemodialysis patients
US20050075597 *13 Sep 20047 Apr 2005Vournakis John N.Vascular access preservation in hemodialysis patients
WO1987002244A1 *8 Oct 198623 Apr 1987Neil Geddes Clarkson HendryTissue growth regulation
WO1988004927A1 *31 Dec 198714 Jul 1988Davirand IncCompositions and formulations containing folic acid, method of treating tissue with folic acid and method for preparing compositions and formulations of folic acid
WO1994022453A1 *21 Mar 199413 Oct 1994Nutramax Lab IncAminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
WO2005112948A1 *16 May 20051 Dec 2005Univ TottoriDrug for remedy or treatment of wound
U.S. Classification514/62
Cooperative ClassificationA61K31/7004
European ClassificationA61K31/7004